Helicobacter pylori Immunoproteomic Profiles in Gastric Cancer

Lusheng Song, Minkyo Song, Charles S. Rabkin, Stacy Williams, Yunro Chung, Jennifer Van Duine, Linda M. Liao, Kailash Karthikeyan, Weimin Gao, Jin G. Park, Yanyang Tang, Jolanta Lissowska, Ji Qiu, Joshua Labaer, M. Constanza Camargo

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Chronic Helicobacter pylori infection is the major risk factor for gastric cancer (GC). However, only some infected individuals develop this neoplasia. Previous H. pylori serology studies have been limited by investigating small numbers of candidate antigens. Therefore, we evaluated humoral responses to a nearly complete H. pylori immunoproteome (1527 proteins) among 50 GC cases and 50 controls using Nucleic Acid Programmable Protein Array (NAPPA). Seropositivity was defined as median normalized intensity ≥2 on NAPPA, and 53 anti-H. pylori antibodies had >10% seroprevalence. Anti-GroEL exhibited the greatest seroprevalence (77% overall), which agreed well with ELISA using whole-cell lysates of H. pylori cells. After an initial screen by H. pylori-NAPPA, we discovered and verified that 12 antibodies by ELISA in controls had ≥15% of samples with an optical reading value exceeding the 95th percentile of the GC group. ELISA-verified antibodies were validated blindly in an independent set of 100 case-control pairs. As expected, anti-CagA seropositivity was positively associated with GC (odds ratio, OR = 5.5; p < 0.05). After validation, six anti-H. pylori antibodies showed lower seropositivity in GC, with ORs ranging from 0.44 to 0.12 (p < 0.05): anti-HP1118/Ggt, anti-HP0516/HsIU, anti-HP0243/NapA, anti-HP1293/RpoA, anti-HP0371/FabE, and anti-HP0875/KatA. Among all combinations, a model with anti-Ggt, anti-HslU, anti-NapA, and anti-CagA had an area under the curve of 0.73 for discriminating GC vs. controls. This study represents the first comprehensive assessment of anti-H. pylori humoral profiles in GC. Decreased responses to multiple proteins in GC may reflect mucosal damage and decreased bacterial burden. The higher prevalence of specific anti-H. pylori antibodies in controls may suggest immune protection against GC development.

Original languageEnglish (US)
Pages (from-to)409-419
Number of pages11
JournalJournal of Proteome Research
Issue number1
StatePublished - Jan 1 2021


  • H. pylori
  • antibody
  • gastric cancer
  • serology

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)


Dive into the research topics of 'Helicobacter pylori Immunoproteomic Profiles in Gastric Cancer'. Together they form a unique fingerprint.

Cite this